After modification for tumor aggressiveness (tumor grade, nodal status, size, age, treatment, PR status, HER-2), hence excluding bias towards detection of inactive cancers (length bias), the avail of screening for the prognosis for BC(breast cancer) patients stayed evident, this indicate that other agents explain the indolent demeanor of BC revealed by screening. This evidence concerns the gene ERBB2 and breast cancer.